NCT05830084 - Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 16, 2023

Primary Completion Date

April 30, 2027

Study Completion Date

October 31, 2027

Conditions

Ewing Sarcoma

Interventions

DRUG

regorafenib tablet

"Regorafenib will be escalated/de-escalated, starting at DL0:~* DL1: 82 mg/m\^2 once daily for 21 days/28 days (max 160mg) (100% of the RP2D)~* DL0 (starting dose): 66 mg/m\^2 once daily for 21 days/28 days (max 120mg) (80% of the RP2D)~* DL-1: 50 mg/m\^2 once daily for 21 days/28 days (max 80mg) (60% of the RP2D)"

Trial Locations (13)

113

RECRUITING

Princess Máxima Center, Utrecht

20133

ACTIVE_NOT_RECRUITING

Istituto Nazionale dei Tumori, Milan

94805

RECRUITING

Gustave Roussy, Villejuif

Unknown

ACTIVE_NOT_RECRUITING

Queensland Children's Hospital, Brisbane

RECRUITING

Monash Children's Hospital, Clayton

RECRUITING

Royal Children's Hospital, Parkville

RECRUITING

CHU Bordeaux, Bordeaux

RECRUITING

Centre Oscar Lambret, Lille

RECRUITING

centre Léon Bérard, Lyon

RECRUITING

Institut Curie, Paris

WA6009

ACTIVE_NOT_RECRUITING

Perth Children's Hospital, Perth

DK-2100

ACTIVE_NOT_RECRUITING

Rigshospitalet, Copenhagen

119-12

ACTIVE_NOT_RECRUITING

Vall d'Hebron University Hospital, Barcelona